Resolute Capital Asset Partners’s Ascendis Pharma A/S ASND Stock Holding History

Resolute Capital Asset Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.6M	Buy	118,627 +20,000	+20%	+$4.67M	13.52%	1
2026 Q1	$22.6M	Buy	98,627 +10,000	+11%	+$2.24M	11.87%	1
2025 Q4	$18.9M	Sell	88,627 -77,045	-47%	-$15.9M	9.13%	1
2025 Q3	$32.9M	Buy	165,672 +5,000	+3%	+$933K	17.23%	1
2025 Q2	$27.7M	Sell	160,672 -6,828	-4%	-$1.11M	14.49%	1
2025 Q1	$26.1M	Buy	167,500 +53,000	+46%	+$7.57M	14.69%	1
2024 Q4	$15.8M	Buy	114,500 +10,000	+10%	+$1.31M	8.48%	3
2024 Q3	$15.6M	Buy	104,500 +57,500	+122%	+$7.77M	8.12%	4
2024 Q2	$6.41M	Hold	47,000	–	–	3.69%	9
2024 Q1	$7.11M	Buy	47,000 +10,600	+29%	+$1.51M	3.71%	8
2023 Q4	$4.58M	Sell	36,400 -1,100	-3%	-$110K	2.99%	10
2023 Q3	$3.51M	Hold	37,500	–	–	2.48%	19
2023 Q2	$3.35M	Hold	37,500	–	–	2.38%	18
2023 Q1	$4.02M	Hold	37,500	–	–	2.94%	14
2022 Q4	$4.58M	Buy	37,500 +7,500	+25%	+$871K	4.09%	10
2022 Q3	$3.1M	Buy	30,000 +10,000	+50%	+$948K	2.78%	12
2022 Q2	$1.86M	Hold	20,000	–	–	1.34%	25
2022 Q1	$2.35M	Buy	+20,000	New	+$2.32M	1.5%	27

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Resolute Capital Asset Partners's ASND Position: Q2 2026 in Review

Resolute Capital Asset Partners increased its Ascendis Pharma A/S (ASND) stake by 20% in Q2 2026, buying an estimated $4.67M and bringing the position to 118,627 shares worth $31.6M. The position accounts for 13.52% of the portfolio, ranked #1.

Resolute Capital Asset Partners first reported a position in ASND in Q1 2022 and has held it in 18 quarters since. The position peaked at $32.9M in Q3 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Resolute Capital Asset Partners held 118,627 shares of Ascendis Pharma A/S worth $31.6M as of Q2 2026.
Resolute Capital Asset Partners bought 20,000 Ascendis Pharma A/S shares in Q2 2026, an estimated $4.67M.
Ascendis Pharma A/S made up 13.52% of Resolute Capital Asset Partners's portfolio in Q2 2026, its #1 holding.
Resolute Capital Asset Partners first reported a position in Ascendis Pharma A/S in Q1 2022 and has held it in 18 quarters since.
Resolute Capital Asset Partners's Ascendis Pharma A/S position peaked at $32.9M in Q3 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q2 2026, filed 14 Aug 2026.